John Charles Sidney

US Patent:

6413517, Jul 2, 2002

Filed:

Jan 21, 1998

Appl. No.:

09/009953

Inventors:

Alessandro Sette - La Jolla CA
John Sidney - San Diego CA
Scott Southwood - Santee CA

Assignee:

Epimmune, Inc. - San Diego CA

International Classification:

A61K 3900

US Classification:

4241851, 4241841, 4241861, 4241931, 424 931, 424 932, 424 9321, 4351723, 4351724, 4352351, 4353201, 435325, 435 6, 514 2, 514 44, 514 15, 530300, 530332, 530327, 530868, 536 231, 536 234, 536 235, 536 2392

Abstract:

The present invention is based on peptide binding specificities of HLA DR4w4, DR1 and DR7. Peptides binding to these DR molecules have a motif characterized by a large aromatic or hydrophobic residue in position 1 (Y, F, W, L, I, V, M) and a small, non charged residue in position 6 (S, T, C, A, P, V, I, L, M). In addition, allele-specific secondary effects and secondary anchors are defined, and these results were utilized to derive allele specific algorithms. By the combined use of such algorithms peptides capable of degenerate DR1, 4, 7 binding were identified.

US Patent:

6413935, Jul 2, 2002

Filed:

Jan 23, 1997

Appl. No.:

08/788822

Inventors:

Alessandro Sette - La Jolla CA
Federico Gaeta - San Rafael CA
Howard M. Grey - La Jolla CA
John Sidney - San Diego CA
Jeffrey L. Alexander - San Diego CA

Assignee:

Epimmune Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 14, 530402, 530403, 530300, 530327, 4241851, 4241931

Abstract:

The present invention provides compositions and methods of inducing immune response in patients. In particular, it provides compositions useful in inducing humoral resposes against desired immunogens, particularly polysaccharides.

US Patent:

6464980, Oct 15, 2002

Filed:

Apr 2, 1996

Appl. No.:

08/627820

Inventors:

John D. Fikes - San Diego CA
Brian D. Livingston - San Diego CA
Alessandro D. Sette - La Jolla CA
John C. Sidney - La Jolla CA

Assignee:

Epimmune Inc. - San Diego CA

International Classification:

A61K 3900

US Classification:

4241851, 4241841, 4242771, 514 2, 514 14, 514 15, 514 21, 530300, 530324, 530326, 530327, 530328

Abstract:

The complete nucleotide and amino acid sequences of the human MAGE-1 antigen are provided. Peptides from residues of the C-terminal are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against MAGE-1 antigens. The peptides are particularly useful in methods for stimulating the immune response of individuals against MAGE-1 antigens associated with melanomas.

US Patent:

6602510, Aug 5, 2003

Filed:

Apr 5, 2000

Appl. No.:

09/543608

Inventors:

John D. Fikes - San Diego CA
Alessandro Sette - La Jolla CA
John Sidney - San Diego CA
Scott Southwood - Santee CA
Esteban Celis - Rochester MN
Elissa A. Keogh - San Diego CA
Robert Chesnut - Cardiff-by-the-Sea CA

Assignee:

Epimmune Inc. - San Diego CA

International Classification:

A61K 3808

US Classification:

4242771, 530324, 530325, 530326, 530327, 530328, 530402, 4241921, 4241931, 424450, 424 9371, 514 2, 514 15, 514 14, 514 13, 514 12

Abstract:

A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4), KVAELVHFL (SEQ. ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7), and, VVLGVVFGI (SEQ. ID. NO: 8).

US Patent:

6689363, Feb 10, 2004

Filed:

Jan 27, 1999

Appl. No.:

09/239043

Inventors:

Alessandro Sette - La Jolla CA
John Sidney - La Jolla CA
Scott Southwood - Santee CA
Maria A. Vitiello - La Jolla CA
Brian D. Livingston - San Diego CA
Esteban Celis - Rochester MN
Ralph T. Kubo - Carlsbad CA
Howard M. Grey - La Jolla CA
Robert W. Chesnut - Cardiff-by-the-Sea CA

Assignee:

Epimmune Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

4241891, 4241851, 4241861, 530324, 530327, 530328

Abstract:

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.

US Patent:

7026443, Apr 11, 2006

Filed:

Aug 15, 2000

Appl. No.:

09/641528

Inventors:

Alessandro Sette - La Jolla CA, US
John Sidney - San Diego CA, US
Scott Southwood - Santee CA, US
Robert Chesnut - Cardiff-by-the-Sea CA, US
Esteban Celis - Rochester MN, US
Howard M. Grey - La Jolla CA, US

Assignee:

Epimmune Inc. - San Diego CA

International Classification:

C07K 7/00

US Classification:

530300, 4241841, 4241921, 4241931, 4241941, 4242041

Abstract:

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

US Patent:

7202351, Apr 10, 2007

Filed:

Nov 8, 2000

Appl. No.:

09/709774

Inventors:

Alessandro Sette - La Jolla CA, US
Federico Gaeta - San Rafael CA, US
Howard M. Grey - La Jolla CA, US
John Sidney - San Diego CA, US
Jeffery L. Alexander - San Diego CA, US

Assignee:

Pharmexa Inc. - San Diego CA

International Classification:

C07H 21/04

US Classification:

536 231, 536 234

Abstract:

The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

US Patent:

7252829, Aug 7, 2007

Filed:

Nov 10, 1998

Appl. No.:

09/189702

Inventors:

Alessandro Sette - La Jolla CA, US
John Sidney - San Diego CA, US
Scott Southwood - Santee CA, US
Esteban Celis - Rochester MN, US

Assignee:

IDM Pharma, Inc. - Paris

International Classification:

A61K 38/08
A61K 38/10
A61K 39/00
C07K 4/12

US Classification:

4242771, 4241851, 424450, 514 2, 514 12, 514 13, 514 14, 514 15, 514 16, 530324, 530325, 530326, 530327, 530328

Abstract:

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e. g. , MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.